Additional file 4 of Efficacy and safety of fremanezumab in patients with migraine and inadequate response to prior preventive treatment: subgroup analyses by country of a randomized, placebo-controlled trial

Additional file 4. Change in Patient-reported Outcomes 4 Weeks After the Third Dose of Study Drug. Change in 6-item Headache Impact Test (HIT-6) and Migraine Disability Assessment (MIDAS) scores and Patient Global Impression of Change (PGIC) responder rates from baseline to 4 weeks after the third dose of study drug. PGIC responder was defined as a patient who reported a rating of 5 to 7 (moderately better, better, or a great deal better) on the PGIC.